[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Wong et al., 2014 - Google Patents

Metals and cholesterol: two sides of the same coin in Alzheimer's disease pathology

Wong et al., 2014

View HTML
Document ID
17617797229675097982
Author
Wong B
Hung Y
Bush A
Duce J
Publication year
Publication venue
Frontiers in Aging Neuroscience

External Links

Snippet

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease. It begins years prior to the onset of clinical symptoms, such as memory loss and cognitive decline. Pathological hallmarks of AD include the accumulation of β-amyloid in plaques and hyperphosphorylated …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Similar Documents

Publication Publication Date Title
Wong et al. Metals and cholesterol: two sides of the same coin in Alzheimer’s disease pathology
Feringa et al. Cholesterol and Alzheimer’s disease; from risk genes to pathological effects
Wang et al. Peptidyl-prolyl cis/trans isomerase Pin1 and Alzheimer’s disease
Boyarko et al. Human tau isoforms and proteolysis for production of toxic tau fragments in neurodegeneration
Hashimoto et al. Tau binding protein CAPON induces tau aggregation and neurodegeneration
Area-Gomez et al. A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease
Sato et al. The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease
Kaur et al. Cystatin C in Alzheimer's disease
Canobbio et al. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease
Vance Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases
Hung et al. Links between copper and cholesterol in Alzheimer's disease
Wang et al. Dysregulation of protein trafficking in neurodegeneration
Kim et al. The role of apolipoprotein E in Alzheimer's disease
Burns et al. Presenilin redistribution associated with aberrant cholesterol transport enhances β-amyloid production in vivo
Tai et al. Levels of Soluble Apolipoprotein E/Amyloid-β (Aβ) Complex Are Reduced and Oligomeric Aβ Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples*[S]♦
Segatto et al. Cholesterol homeostasis failure in the brain: implications for synaptic dysfunction and cognitive decline
Aso et al. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease
Kitazawa et al. Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD
Nalivaevaa et al. Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid‐degrading enzymes
Grimm et al. The role of APP proteolytic processing in lipid metabolism
Shimada et al. Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion
Huang Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models
Becker-Pauly et al. The metalloprotease meprin β is an alternative β-secretase of APP
Aucoin et al. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer’s disease
Wild et al. Structure and synaptic function of metal binding to the amyloid precursor protein and its proteolytic fragments